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ABSTRACT
Breast carcinoma is the most frequently diagnosed cancer among women and causes 
over 400,000 deaths each year worldwide. Current treatments such as chemotherapy 
are not selective for cancerous tissues but are destructive to normal tissues as well. 
This causes a range of side effects including pain, nausea, hair loss, weakness, and 
more. Inactivation of p53 is a very common mutation within human cancer cells. The 
ability to activate the p53 pathway, which protects cells from tumor formation, is lost 
in 50% of cancers. Due to the prevalence of this mutation, p53 is a uniquely valuable 
target for applied research. Alpha mangostin is an extract from a southeast Asian fruit, 
Garcinia mangostana. It has potential to be an effective p53 activator in which the 
small molecule disrupts the binding of p53 to MDM2, a negative regulator, inducing 
the p53 cascade, which results in cell cycle arrest for low level stressors. This protects 
the cells from paclitaxel, a chemotherapy agent that only kills actively dividing cells. 
Here, we hypothesized that alpha mangostin protects wild-type, but not p53 (-/-
), MCF10A breast cancer cells from the chemotherapeutic agent paclitaxel. When 
MCF10A wild-type cells were cotreated with alpha mangostin and paclitaxel, alpha 
mangostin exhibited a protective effect on the cells. However, when MCF10A P53 
knockout cells were treated with alpha mangostin, cell viability decreased, indicating a 
loss of protective effect in the p53 distressed cancer cells. These results further support 
treatments that target chemoprotection via p53 pathway in wild-type cells, and the use 
of alpha mangostin warrants further study.
LITERATURE REVIEW
Breast carcinoma and treatments
The development of cancer is a multistep process that involves complex interactions 
between host and tumor tissue. The process involves oncogene activation as well as 
immunosuppression, leading to uncontrolled cell growth despite damaged DNA (Wang 
2010). Genome instability contributes to cancer development due to mutations in DNA 
damage response pathways, which are mediated through the tumor suppressor p53 
(Reinhardt & Schumacher, 2012).
Breast carcinoma is the most frequently diagnosed cancer among women and causes 
over 400,000 deaths yearly worldwide (Walerych, Napoli, Collavin, & Del Sal, 
2012). Metastasis accounts for a large majority of the deaths that result from breast 
cancer, mostly to lymph nodes, lungs, and bones. The complexity of cancer leads to 
difficulties in treatment. Many of these difficulties are due to the nonselective nature 
of the treatment, which cause cell toxicity in noncancerous cells. Treatment plans are 
dependent on the stage and characteristics of the cancer as well as the age, menopausal 
status, and risk benefit analysis associated with each option. Based on a study in 2017, 
stage I and II patients most often receive breast conserving surgery. Stage III patients 
most often receive a mastectomy, radiation therapy, as well as chemotherapy with a 
five-year survival rate of 72%. Stage IV patients most often receive radiation therapy 
and or chemotherapy with a five-year survival rate of about 22% (American Cancer 
Society, 2017).
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In order to delay the progression of breast cancer and increase the longevity of patients, 
less toxic yet effective chemotherapeutic agents are needed to limit the debilitating 
side effects while also improving outcomes (Shibata et al., 2011). These side effects 
include pain, lymphedema, musculoskeletal symptoms, bone loss and osteoporosis, 
heart problems, new cancers, blood clots, infertility, and loss of memory and cognitive 
function. (American Cancer Society, 2017).
Currently, conventional treatments such as radiation, chemotherapy, and surgery have 
not been entirely effective against the high incidence and low survival rates of breast 
cancer due to its complex nature (Moongkarndi et al., 2004). Research has established 
that combinations of drugs are more effective than one drug alone for the treatment of 
early-stage breast cancer. An example of such treatment is Trastuzumab, a monoclonal 
antibody that directly targets the human epidermal growth factor 2 (HER2) protein.
Figure 1. Various outcomes of the p53 pathway. Different causes, such as those of mild physiological stress or severe 
stress, interrupt the mdm2 and p53 binding and result in various outcomes such as DNA repair, growth arrest, apoptosis, 
and more (Vogelstein, Hughes, Kimmel, & Cancer, 2013).
When combined with chemotherapy, this treatment was found to reduce the risk 
of recurrence by 52% and death by 33% for patients who overproduce the growth 
promoting protein HER2/neu (American Cancer Society, 2017). This leads the 
scientific community to search for other potential therapeutic approaches including 
drug combinations to treating this malignancy and many other cancers that continue to 
evade conventional treatments.
P53 gene and cascade
The main function of p53 is to promote genetic stability and prevent the formation of 
tumors. When a cell is under stress, it induces cell death through apoptosis for severe 
stress or cell arrest and subsequent DNA repair for mild stress in order to prevent 
malignant growth. Under normal conditions, p53 levels are low and the binding to 
mouse double minute 2 homolog (MDM2) targets it to the proteasome for rapid 
degradation and inhibition of its transcriptional activity (Burgess et al., 2016).
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When stress occurs, binding to the regulatory protein MDM2 is disrupted due to P53 
phosphorylation, which leads to p53 accumulation and subsequent transcription of 
numerous genes, including the gene that encodes the cyclin-dependent kinase inhibitor 
(CKI) protein p21. P21 binds and inactivates G1/S-Cdk complexes, arresting the cell 
in G1 for DNA repair.
Figure 2. The p53 cascade. This figure is a simple representation of a cell’s response to stress that result in DNA dam-
age. The first step is phosphorylation of p53 to affect its binding to mdm2. This process also includes a key player in 
the process, p21, which is a Cdk inhibitor. The end result is an inactivation of the G1.S-Cdk and D-Cdk complex with 
p21. (Vogelstein, Hughes, Kimmel, & Cancer, 2013).
P53 mutation and treatments
Inactivation of p53 is a very common feature of human cancer cells (Lane, Cheok, & 
Lain, 2010). About 50% of adult cancer has p53 inactivated (by mutation or deletion), 
while the other 50% has suppressed wild-type p53 function (Choong, Yang, Lee, & 
Lane, 2009). On average, p53 is mutated in 20% of tumors in breast cancer. Though 
the frequency of mutation is lower in breast cancer cells, p53 inactivation has been 
seen in some breast cancers without a mutation. The pathway has been shown to be 
affected by alterations in upstream regulatory proteins and downstream p53-induced 
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proteins (Gasco, Shami, & Crook, 2002). In breast cancer, this mutation is associated 
with a more aggressive disease and worse overall survival according to several studies 
(Gasco et al., 2002).
The ability to activate the p53 pathway that protects cells from tumor formation is lost 
in cells with p53 mutations. Most of these mutations occur as a result of a substitution 
of single amino acids in the central region of the p53 protein, which causes many 
variants (Walerych et al., 2012). Indeed, rapid malignant cell growth, which leads 
to many different cancer types, often involves a defective p53 gene, which is the 
transcriptional activator that works to suppress tumors in normal tissues (Muller & 
Vousden, 2014). In breast cancer, mutant p53 is involved in many processes associated 
with cancer development such as early tumorigenesis, tumor growth and development, 
and metastasis (Walerych et al., 2012). In clinical practice, molecular pathological 
analysis of the tumors of the structure and expression and constituents of the p53 
pathway is likely to have value in diagnosis, in prognostic assessment and, ultimately, 
in treatment of breast cancer (Gasco et al., 2002).
Chemotherapy and mechanism of chemoprotection
Chemotherapy induces many adverse effects in patients because of normal cell 
toxicity, resulting at least in part from p53 activation and apoptosis induction in normal 
proliferating cells/tissues such as bone marrow, lymphoid organs, hair follicles, and 
epithelium lining of the small intestine (Wang & Sun, 2010). An important aspect of 
chemotherapy is that it kills actively dividing cells. In particular, paclitaxel inhibits 
microtubule function, which kills cells as they enter mitosis (Blagosklonny, 2002). 
Microtubules are essential to the process of mitosis, as they separate chromosomes 
to opposite sides of the cell during anaphase. When paclitaxel inhibits the ability for 
the chromosomes to be separated during the division process, the cell is inactivated 
and eventually is killed. Therefore, wild-type cells treated with the p53 activator are 
arrested in G1 and do not enter into mitosis; therefore, the chemotherapy selectively 
kills p53-deficient cancer cells. This mechanism can be experimentally controlled with 
the use of p53 activators to arrest p53 wild-type cells and protect against the harmful 
effects of chemotherapeutic agents on noncancerous cells. 
P53 activator current research
Due to the prevalence of this mutation, p53 is a uniquely valuable target for applied 
research (Vogelstein et al., 2013). Therefore, much research has gone into both 
therapeutic strategies to restore mutant to wild-type p53 and pretreatment of cancer 
cells with p53 activators that arrest noncancerous p53-normal proliferating cells without 
impacting the cell cycle of cells with a p53 mutation, thus allowing for selective killing 
of cancerous cells. 
Current research on this type of treatment has led to the discovery of small molecules 
that directly or indirectly activate p53. Some p53 activation has been achieved in the 
clinic. The most advanced of these are the p53 mdm2 interaction inhibitors. The first 
class of small molecule mdm2 inhibitors discovered was nutlin-3a, which binds to the 
hydrophobic cleft in the N-terminus of mdm2, preventing its association with p53 and 
initiating the cascade. Since this discovery of nutlin-3a, many more related compounds 
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have been tested, some of which have now made it to the preclinical stage. This stage 
will better assess the biological effects and toxicity of the treatment to patients (Burgess 
et al., 2016). As research continues and understanding of p53 response increases, 
development will continue allowing for powerful drug combinations that may increase 
the selectivity and safety of chemotherapy by selective protection of normal cells and 
tissue (Lane et al., 2010).
Alpha mangostin as a chemoprotectant
Alpha mangostin is a p53 activator that is isolated from the carp of the Garcinia 
mangostana (Mangosteen fruit), which is native to Thailand and traditionally used for 
antioxidant, antitumoral, antiallergic, anti-inflammatory, antibacterial, and antiviral 
medicinal purposes (Pedraza-Chaverri, Cárdenas-Rodríguez, Orozco-Ibarra, & Pérez-
Rojas, 2008). This extract is known to inhibit the binding of p53 to MDM2, a negative 
regulator of p53.
In one study in 2011, alpha mangostin was used to reduce tumor growth and lymph 
node metastasis in an immunocompetent xenograft model of metastatic mammary 
cancer with a p53 mutation. The study showed that treatment with 20 mg/kg/day 
alpha mangostin resulted in prolonged survival rates and increased inhibition of tumor 
growth and lymph node metastasis (Shibata et al., 2011). This reveals that this extract 
at high concentrations can potentially be a successful treatment for p53 mutated cancer 
types. Meanwhile, at lower concentrations, alpha mangostin has the potential to act as 
a chemoprotectant to wild-type cells. One study tested the chemoprotection of alpha 
mangostin on wild-type BHK cells. The results supported the hypothesis that alpha 
mangostin can be used to protect cells from the cytotoxic effects of chemotherapy 
(Wojciechowski, 2017). However, the effect on breast cancer cell lines at low 
concentrations is not known. Here, this research seeks to determine whether or not 
the alpha mangostin pretreatment would be an effective strategy for chemoprotection 
of wild-type cells by testing whether or not the cancer cells are also protected. If 
the data indicate that the cancerous cells are not protected, this p53 activator could 
potentially be a successful pretreatment before chemotherapy for selective cancer 
killing. I hypothesize that alpha mangostin, a p53-dependent chemoprotectant, protects 
wild-type cells but not those with a p53 mutation from the chemotherapeutic agent 
paclitaxel.
MATERIALS AND METHODS
Culturing of MCF10A cells
Cell culture protocol was based on the ATCC© Thawing, Propagating, and 
Cryopreserving Protocol (“Thawing, Propagating, and Cryopreserving Protocol: 
MCF10A-JSB Breast epithelium,” 2012). MCF10A p53 Wild-type and p53 knockout 
(-/-) human breast cancer cells were cultured in Dulbecco’s Modified Eagle’s Medium 
supplemented with cholera toxin from V. cholera, insulin solution, epidermal growth 
factor, 50 uM hydrocortisone solution, and horse serum at 37°C. PBS was used to rinse 
the wells before lifting. Trypsin-EDTA solution was used to lift cells.
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Determining the toxicity of alpha mangostin and paclitaxel
Cells were treated at various levels of alpha mangostin and paclitaxel to create a dose 
response curve and toxicity curve and determine workable concentrations for the 
dual treatment experiments. For the dual treatment, cells were treated with various 
concentrations of alpha mangostin, ranging from 0 to 0.25 uM, for twenty-four hours 
followed by a twenty-four-hour dual treatment of alpha mangostin and 15 nM paclitaxel. 
Differentiating between viable, apoptotic, and necrotic cells
Cells were stained with Hoechst, YO-PRO 1, and propidium iodide to differentiate 
between viable, apoptotic, and necrotic cells. Data was collected on cell viability 
using differential fluorescent staining. The differences were shown through fluorescent 
microscopy with Hoechst, propidium iodide, and YO-PRO-1 stains. The Hoechst stain 
only stains normal healthy cells. The next two, propidium iodide and YO-PRO-1, only 
stains necrotic and apoptotic cells, respectively. Through these three stains, I will be 
able to only evaluate the attached cells for comparison. Quantitatively, the cells stained 
with Hoechst stain were used for the results section. However, the two other stains are 
shown in the figures with photos. Representative pictures at 10x were taken blindly by 
a professor in order to eliminate bias and counted using the fluorescent cell counting 
program.
Development and use of cell counting program
The program used to count the cells was developed by Evan Dexter using Microsoft 
Visual Studio in C# language. The code for this program is shown in Appendix 1. It 
works by use of an algorithm that examines the color values of the picture’s pixels. 
Pixels with high values of the color being counted are flagged as potential cell locations. 
Various user-controlled parameters are then used to refine the number of cells from the 
initial list. Changing the parameters makes it possible to count the number of cells for 
different types of cells and conditions. The resulting count is displayed to the user as 
both a sum total and a marker on each cell location (Dexter 2019).
RESULTS
Data shown in the results section come from representative photos taken at 100x on 
a fluorescent microscope and analyzed using a double-blind method. Typical methods 
such as the cell hemocytometer were not able to be used due to difficulties lifting 
the cells without killing them. Therefore, a program was developed that would 
count representative photos to have an idea of cell viability in each of the treatment 
wells (Appendix 1). Viable cells were counted as indicated by the blue Hoechst 
stain. Concentration ranges for toxicity curves and dose response curves were 
based upon previous research using these treatments with baby hamster kidney cells 
(Wojciechowski, 2017).
Single treatment results for wild-type cells (p53 pathway intact)
We first wanted to determine the effect of the chemotherapeutic drug, paclitaxel, 
on the MCF10A wildtype cells. This procedure allowed for the determination of a 
concentration that would be suitable for dual treatment with alpha mangostin.
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Increasing concentrations of alpha mangostin caused a decrease in the number of cells 
in the well (Figures 3 and 4). There were not many floating dead cells in the wells, 
which indicate that the decrease in cell number was likely due to cell cycle arrest. 
The control well had a variable number of cells in each well, as indicated by the large 
error bars in Figure 4. If experimental error did not have an effect on the results of 
the control well then very low concentrations of paclitaxel had a mitogenic effect on 
the wild-type MCF10A cell line. The chosen concentration of paclitaxel for the dual 
treatment was 15 Nm, as higher concentration did not give a sufficient number of cells 
to allow for variable cell counts with lower standard error.
Figure 3. Fluorescent micros-
copy of MCF10A wild-type 
cells after treatment with 
paclitaxel. A is the control, B is 
10 nM, C is 25 nM, and D is 35 
nM. Increase in concentration 
led to a decrease in live cell 
count.
Figure 4. Wild-type MCF10A 
paclitaxel toxicity curve. 
Cells were treated with 
concentrations ranging from 
0-35 nM for twenty-four 
hours, and the cell count per 
field of view was recorded per 
well. The 5, 10, and 15 nM 
concentration of paclitaxel 
had a mitogenic effect on the 
cells with toxicity beginning 
at 25 nM. 
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We next sought to determine the effect of alpha mangostin on cell viability for the 
wild-type MCF10A cells. This experiment was also done in order to determine an 
acceptable range for the dual treatment for this cell line with the chemotherapeutic 
agent, paclitaxel.
Figure 5. Fluorescent 
microscopy of MCF10A
wild-type cells after 
treatment with alpha 
mangostin. Top left is the 
control, top right is 0.05 μM, 
bottom left is 0.15 μM, bottom 
right is 0.25 μM. Increase in 
concentration led to a decrease 
in live cell count
The MCF10A wild-type cells responded in a dose dependent manner (Figure 
5 and 6). In addition to the control, varying concentrations ranging from 0.05 
to 0.25 were used because it gave a suitable range that had variable cell counts.
Figure 6. Wild-type 
MCF10A alpha mangostin 
dose response curve. Cells 
were treated with varying 
concentrations of alpha 
mangostin for twenty-four 
hours and counted using the 
fluorescent cell counting 
program.
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Dual treatment results for wild-type cells (p53 pathway intact)
The final experiment for the wild-type cells was the dual treatment with alpha 
mangostin for twenty-four hours followed by a combination of alpha mangostin 
and paclitaxel for another twenty-four hours.
Figure 7. Wild-type MCF10A alpha mangostin and paclitaxel dual treatment. Cells were treated with varying 
concentrations of alpha mangostin for 24 hours and counted using the fluorescent cell counting program.
Cells treated with alpha mangostin alone and those cotreated with paclitaxel 
yielded similar cell counts (Figure 7). While these results indicate a negligible 
effect of alpha mangostin as a chemoprotectant, we also observed a wide variety 
of experimental error as will be discussed further below.
Figure 8. Fluorescent microscopy of wild-type MCF10A paclitaxel treatment vs dual treatment with alpha 
mangostin. Left is the paclitaxel only treatment and right is the alpha mangostin paclitaxel dual treatment.
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Single treatment results for MCF10A p53 (-/-) cells
P53 is known to be an important regulator of cell cycle arrest and as noted 
above is often absent in numerous cancers. We therefore wanted to determine 
the role of a chemoprotectant such as alpha mangostin on p53 knockout cells 
(Figures 9 and 10). The concentration range used was slightly larger than that 
used for the wild-type cells to gain a better understanding of the effect of the 
concentration on the treatment.
Figure 9. Fluorescent microscopy of MCF10A p53 (-/-) cells after treatment with alpha mangostin. Top left 
is the control, top right is 0.1 μM, bottom left is 0.5 μM, bottom right is 1 μM. Dark grey cells indicate live cells 
stained with Hoechst, and light grey cells indicate apoptotic cells, and black cells indicate necrotic cells. Increasing 
concentrations led to a decrease in live cell count.
In addition to quantitative data, the wells were qualitatively assessed through a 
blinded observation to determine the approximate cell viability (Figure 11). It 
was important to perform this study for this experiment because the obtained 
counts for Figures 9 and 10 were not particularly representative. This is 
because photos were taken at the edges of the wells since the middle of the well 
had limited consistency in all treatments. Viability was greatly diminished at 
concentration of 0.25 or greater, which is in contrast to what was observed with 
MCF10A wild-type cells.
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Figure 10. MCF10A p53 (-/-) alpha mangostin dose response curve. Cells were treated with varying 
concentrations of alpha mangostin for twenty-four hours and counted using the fluorescent cell counting program.
Figure 11. Qualitative observation of percent viability for increasing treatments of alpha mangostin on 
MCF10A p53 (-/-) cells. Observations of this percentage were estimated using a blind study method.
12
ELAIA, Vol. 2 [2019], Art. 16
https://digitalcommons.olivet.edu/elaia/vol2/iss1/16
265
DISCUSSION
Through induction of p53-dependent G2 arrest, pretreatment can prevent cell death 
caused by microtubule-inhibiting drugs such as paclitaxel. This would allow for 
selective killing of p53 mutant cancer cells (Blagosklonny, 2002). In order to assess 
the chemoprotective abilities of alpha mangostin, we performed several experiments 
on  MCF10A wildtype and p53 (-/-)  breast cancer cells. When working with this cell 
line, a lot of troubleshooting and method alterations went into the process of creating 
the experiments. This is important to note because the major time commitment for this 
troubleshooting did not allow for duplication of the experiments. In order to fully draw 
conclusions from this research, one must duplicate the data in order to gain confidence 
in the results presented. Also, it is important to note that the key findings presented in 
Figure 11 came from a double blinded study to avoid bias.
To begin, the MCF10A wildtype cells were treated with both alpha mangostin and 
paclitaxel separately to create a toxicity and dose response curve in order to determine 
a workable range of concentrations for alpha mangostin and an optimum concentration 
of paclitaxel for the dual treatment. As shown in Figure 4, a 15 nM concentration of 
paclitaxel had higher confidence, shown by smaller error bars, and had a significant 
fraction of less cells than the 5 nM treatment. The mitogenic effect of lower doses in 
contrast to the low number of cells in the control well may be a result of experimental 
error. This concentration has the potential to give room for variation of cell number 
when pretreated with alpha mangostin. Thus, the 15 nM concentration was chosen to 
be the fixed paclitaxel concentration for the dual treatment.
Figure 6 shows that alpha mangostin responds in a dose dependent manner. These 
concentrations were shown to be effective to be used for the dual treatments. Therefore, 
the next experiment included a dual treatment in which cells were treated with 
concentrations of 0.00 μM to 0.25 μM of alpha mangostin on day 1 and treated with 
both alpha mangostin and 15 nM paclitaxel on day 2 (Figure 7). The results of this 
dual treatment show similar cell counts for cultures treated with and without paclitaxel, 
indicating that alpha mangostin is able to effectively protect cells from the normally 
cytotoxic effects of paclitaxel. This conclusion is based on the paclitaxel toxicity curve 
that shows that adding each subsequent concentration of paclitaxel should decrease 
cell number. However, the cells treated with alpha mangostin and no paclitaxel and 
the cells that were dual treated had very similar values. Overall, the wells that were 
pretreated with alpha mangostin had a much larger live cell count than the well that 
received no alpha mangostin pretreatment before it was treated with paclitaxel (Figure 
8). Because the wild-type cells are also representative of typical human breast cells 
with wild-type p53, these experiments indicate that human breast cells will be protected 
from paclitaxel by alpha mangostin.
The second section of results evaluates the effect of pretreatment of p53 knockout 
MCF10A cells to ensure that these cells are not protected by the alpha mangostin. If 
the alpha mangostin showed a similar protective effect, then it would not be a useful 
selective treatment for breast cancer. To explore the relationship between the knockout 
cells and the alpha mangostin, a dose response treatment, ranging from 0 to 1 μM alpha 
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mangostin, was administered to knockout cells for twenty-four hours (Figure 10). 
Based on the mechanism of p53 activators, which includes inhibition of mdm2-p53 
interaction in the normal pathway, cell count numbers were expected to be consistent 
in different concentrations of alpha mangostin. However, number of cells decreased 
with increasing alpha mangostin concentration. Further analysis revealed that the wells 
with higher concentrations of alpha mangostin had many dead cells that were floating 
and thus not recognized by the fluorescent microscope. These dead cells indicate that 
the low number of cells at high concentrations is not due to cell arrest, but rather from 
cell toxicity. The decrease in cell number is shown in Figures 9, 10 and 11. Figure 10 
contains quantitative data that shows a relative decrease in cell number correlates to 
an increase in concentration. Figure 11 contains a qualitative observation of percent 
viability for increasing treatments of alpha mangostin on MCF10A p53 (-/-) cells. The 
percent confluence decreased as alpha mangostin increased. Overall, these data show 
that the number of cells depends on the concentration of the alpha mangostin in a dose 
dependent manner.
Overall, the range of concentration of alpha mangostin between 0.1 μM to 0.25 μM 
showed a protective benefit to wild-type MCF10A breast cancer cells. Furthermore, the 
same concentration range decreased cell viability of the MCF10A p53 knockout cell line. 
This indicates that alpha mangostin has potential as a selective cancer treatment when 
paired with the chemotherapeutic drug paclitaxel. While these results are encouraging 
and suggest that alpha mangostin is a potential chemoprotectant for chemotherapy, it 
is important to acknowledge the limitations of this research. Due to difficulties and 
troubleshooting, only one trial for each of these various treatments was completed. 
Therefore, in order to fully validate this research, it must be replicated to eliminate any 
results which came from experimental error. Along with replication of this experiment, 
it would be beneficial to continue the knockout MCF10A p53 (-/-) study and perform a 
toxicity curve with paclitaxel in order to perform a dual treatment study. Furthermore, 
these experiments should be performed on several different cell lines to evaluate the 
effectiveness of alpha mangostin on different cell types and cancers. Further research 
is required to explore the promising pretreatment to chemotherapy, alpha mangostin.
Although many treatments exist for cancer, scientists are always looking for better and 
more effective options for patients. When evaluating treatment plans, patients must 
consider both the effectiveness of the treatment and the negative side effects of each 
treatment option. While chemotherapy has shown to be an effective and aggressive 
treatment option, it is not selective for that tissue, and therefore has many harsh 
side effects including pain, lymphedema, musculoskeletal symptoms, bone loss and 
osteoporosis, heart problems, new cancer development, blood clots, infertility, and loss 
of memory and cognitive function (American Cancer Society, 2017). This research, 
as well as other studies, show that alpha mangostin has potential as a p53 activation 
pretreatment before chemotherapy to limit these side effects.
The p53 gene is a great potential target for cancer treatment because it is the most 
frequently altered gene in human cancers (Shibata et al., 2011). If alpha mangostin 
can be used as a tool for chemoprotection in a p53-dependent manner in breast cancer 
development, then it would enable doctors to treat patients with higher concentrations 
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of chemotherapy without harming healthy tissue. It would also potentially have 
implications in treatments of other types of cancer, such as some uterine, ovarian, and 
lung cancers, which also have a high prevalence of p53 mutations. Alpha mangostin 
offers a more natural treatment option that can be easily translated to clinical use 
because it is already FDA approved. Overall, this study shows that alpha mangostin 
warrants further research to better understand its effectiveness as a pretreatment for 
chemotherapy.
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APPENDIX 1
Please see the complete version of this paper on Olivet Nazarene University’s Digital 
Commons for the fluorescent cell counting software code.
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